Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

Original Article

J.I. Silverberg, E. Guttman-Yassky, D. Thaçi, A.D. Irvine, L.S. Gold, A. Blauvelt, E.L. Simpson, C.-Y. Chu, Z. Liu, R.G. Lima, S.G. Pillai, and J. Seneschal

N Engl J Med 2023;388:1080-1091

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
03/22/2023
Course expires: 
03/23/2025
Take course

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Take course